Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of the October 20, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against Fractyl Health, Inc. (“Fractyl” or the “Company”) (NASDAQ: GUTS).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826537253/en/

[You may also click here for additional information]

WHY: Faruqi & Faruqi, LLP, a leading national securities law firm, informs investors of the federal securities class action on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, inclusive (the “Class Period”).

WHAT TO DO NEXT: To learn more about the Fractyl class action, go to www.faruqilaw.com/GUTS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). A class action lawsuit has already been filed.

If you wish to serve as lead plaintiff, you must move the Court no later than October 20, 2026. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

THE ALLEGATIONS:

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) Revita was less effective than Defendants had led investors to believe, and/or operational issues at one or more of the REMAIN-1 Midpoint Cohort’s clinical sites compromised the integrity of its efficacy results; (ii) accordingly, Revita’s clinical, regulatory, and commercial prospects were overstated, as was the REMAIN-1 Midpoint Cohort’s ability to assess Revita’s efficacy; and (iii) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Fractyl’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Frequently Asked Questions (FAQ) for Investors Regarding the Fractyl Securities Class Action Lawsuit

Who may be eligible to participate in the lawsuit?

Investors who purchased or acquired Fractyl (NASDAQ: GUTS) between January 13, 2025 and January 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

How much did Fractyl stock drop?

Following the alleged corrective disclosures, Fractyl shares fell approximately [% on DATE], as described in the complaint.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Fractyl Health, Inc. securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

Media gallery

About The Author
Business Wire